

Resource Summary Report

Generated by [kravitz2](#) on Jul 31, 2026

BioClinica

RRID:SCR_003789

Type: Tool

Proper Citation

BioClinica (RRID:SCR_003789)

Resource Information

URL: <http://www.bioclinica.com/>

Proper Citation: BioClinica (RRID:SCR_003789)

Description: Pennsylvania-based company supporting pharmaceutical and medical device innovation with imaging core lab, EDC, IVR / IWR, CTMS, and supply chain forecasting and optimization. Its initial service was medical imaging for clinical trials. It is used to capture, collect, control quality, provide blinded reading services to the final delivery to the sponsor company and to the FDA or EMEA if required for medical images in a wide range of imaging modalities. (Wikipedia)

Abbreviations: BioClinica

Synonyms: BioClinica Inc.

Resource Type: commercial organization

Keywords: clinical trial, pharmaceutical, medical device, medical imaging, cardiac safety, clinical

Resource Name: BioClinica

Resource ID: SCR_003789

Alternate IDs: Crossref funder ID: 100007742, ISNI: 0000 0004 0602 1531, Wikidata: Q4914605, grid.430790.9, nlx_158082

Alternate URLs: <https://ror.org/03t95yr58>

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260725T190542+0000

Ratings and Alerts

No rating or validation information has been found for BioClinica.

No alerts have been found for BioClinica.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 101 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Huang RY, et al. (2025) Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 43(10), 1210.

Rash BG, et al. (2025) Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial. *Nature medicine*, 31(4), 1257.

Chen T, et al. (2025) Integration of longitudinal load-bearing tissue MRI radiomics and neural network to predict knee osteoarthritis incidence. *Journal of orthopaedic translation*, 51, 187.

Cosman F, et al. (2025) Probability of achieving bone mineral density treatment goals with denosumab treatment in postmenopausal women with osteoporosis. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 40(6), 766.

Bjerre-Bastos JJ, et al. (2025) The Impact of Weight-bearing Exercise, Non-Weight-bearing Exercise, and Cardiovascular Stress on Biochemical Markers of Cartilage Turnover in Patients With Mild to Moderate Knee Osteoarthritis - A Sequential, Cross-Over, Clinical Study. *Cartilage*, 16(2), 159.

Chen K, et al. (2025) Frontal plane mechanical leg alignment estimation from knee x-rays using deep learning. *Osteoarthritis and cartilage open*, 7(1), 100551.

Lazli L, et al. (2025) Improved Alzheimer Disease Diagnosis With a Machine Learning Approach and Neuroimaging: Case Study Development. *JMIRx med*, 6, e60866.

McClung MR, et al. (2025) Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 40(2), 193.

Lane J, et al. (2024) Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. *Osteoporosis international : a*

journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 35(7), 1195.

Meyer MR, et al. (2024) Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and A β 42/40 ratio to identify presence of brain amyloid. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(5), 3179.

Salcudean A, et al. (2024) The Role of Systemic Family Psychotherapy in Glycemic Control for Children with Type 1 Diabetes. *Children (Basel, Switzerland)*, 11(1).

Brice NL, et al. (2024) CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial. *EClinicalMedicine*, 77, 102882.

Hey JA, et al. (2024) Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease. *Drugs*, 84(7), 811.

Glorieux FH, et al. (2024) Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 39(9), 1215.

Murina F, et al. (2023) Performance and Safety of a New Medical Device (Polybactum) for Reducing the Recurrence Rate of Bacterial Vaginosis: Protocol for a Multicenter, Open-Label, Noncontrolled International Clinical Trial (POLARIS Study). *JMIR research protocols*, 12, e42787.

Ndhlovu LC, et al. (2023) Retroelement-Age Clocks: Epigenetic Age Captured by Human Endogenous Retrovirus and LINE-1 DNA methylation states. *bioRxiv : the preprint server for biology*.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. *Cell reports. Medicine*, 4(12), 101302.

Hans D, et al. (2023) Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, 34(6), 1075.

Adler J, et al. (2023) Validating the Simplified Endoscopic Mucosal Assessment for Crohn's Disease: A Novel Method for Assessing Disease Activity. *Inflammatory bowel diseases*, 29(7), 1089.

Niazi SK, et al. (2023) The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives. *Drug design, development and therapy*, 17, 2691.